

# United States of America

United States Patent and Trademark Office

# ONCOBODY

**Reg. No. 7,376,666**

**Registered May 07, 2024**

**Corrected Dec. 17, 2024**

**Int. Cl.: 1, 5, 42, 44**

**Service Mark**

**Trademark**

**Principal Register**

LinXis B.V. (NETHERLANDS LIMITED LIABILITY COMPANY)  
Noordhollandstraat 71  
AS AMSTERDAM, NETHERLANDS NL-1081

CLASS 1: Chemical additives for use in the manufacture of pharmaceuticals; chemical preparations for use in the manufacture of pharmaceuticals; active chemical ingredients for use in the manufacture of pharmaceuticals; carrier excipients for use in the manufacture of pharmaceutical preparations

CLASS 5: Drug delivery agents in the form of powders, tablets and capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; biochemical medicines for the treatment of cancer; chemical preparations for pharmaceutical purposes, namely, for the treatment of cancer; diagnostic agents for pharmaceutical purposes; pharmaceutical substances and preparations for the treatment of cancer

CLASS 42: Pharmaceutical research services; scientific research in the nature of conducting clinical trials for pharmaceuticals for others; pharmaceutical research and development; pharmaceutical product evaluation; consultancy relating to pharmaceutical research and development; laboratory research services relating to pharmaceuticals; providing information about the results of clinical trials for pharmaceuticals; providing information about medical and scientific research in the field of pharmaceuticals; research services in the field of proteins, antibodies, microorganisms and cells; research and development services in the field of antibody technology; design and development of medical technology

CLASS 44: In vitro analysis for medical and pharmaceutical use, namely, analysis for medical diagnostic or treatment purposes; in vitro testing for medical and pharmaceutical use, namely, testing for medical diagnostic or treatment purposes; consultancy and information services provided via the Internet relating to pharmaceutical products, namely pharmaceutical [ consultatio ] \* consultation \*

THE MARK CONSISTS OF STANDARD CHARACTERS WITHOUT CLAIM TO ANY PARTICULAR FONT STYLE, SIZE OR COLOR

PRIORITY DATE OF 10-03-2022 IS CLAIMED

OWNER OF INTERNATIONAL REGISTRATION 1727931 DATED 02-02-2023,  
EXPIRES 02-02-2033

The wording "ONCOBODY" has no meaning in a foreign language.

SER. NO. 79-368,861, FILED 02-02-2023



Acting Director of the United States Patent and Trademark Office



**REQUIREMENTS TO MAINTAIN YOUR FEDERAL TRADEMARK REGISTRATION**

**WARNING: YOUR REGISTRATION WILL BE CANCELLED IF YOU DO NOT FILE THE DOCUMENTS BELOW DURING THE SPECIFIED TIME PERIODS.**

**Requirements in the First Ten Years\***

**What and When to File:**

- **First Filing Deadline:** You must file a Declaration of Use (or Excusable Nonuse) between the 5th and 6th years after the registration date. See 15 U.S.C. §§1058, 1141k. If the declaration is accepted, the registration will continue in force for the remainder of the ten-year period, calculated from the registration date, unless cancelled by an order of the Commissioner for Trademarks or a federal court.
- **Second Filing Deadline:** You must file a Declaration of Use (or Excusable Nonuse) and an Application for Renewal between the 9th and 10th years after the registration date.\* See 15 U.S.C. §1059.

**Requirements in Successive Ten-Year Periods\***

**What and When to File:**

- You must file a Declaration of Use (or Excusable Nonuse) and an Application for Renewal between every 9th and 10th-year period, calculated from the registration date.\*

**Grace Period Filings\***

The above documents will be accepted as timely if filed within six months after the deadlines listed above with the payment of an additional fee.

**\*ATTENTION MADRID PROTOCOL REGISTRANTS:** The holder of an international registration with an extension of protection to the United States under the Madrid Protocol must timely file the Declarations of Use (or Excusable Nonuse) referenced above directly with the United States Patent and Trademark Office (USPTO). The time periods for filing are based on the U.S. registration date (not the international registration date). The deadlines and grace periods for the Declarations of Use (or Excusable Nonuse) are identical to those for nationally issued registrations. See 15 U.S.C. §§1058, 1141k. However, owners of international registrations do not file renewal applications at the USPTO. Instead, the holder must file a renewal of the underlying international registration at the International Bureau of the World Intellectual Property Organization, under Article 7 of the Madrid Protocol, before the expiration of each ten-year term of protection, calculated from the date of the international registration. See 15 U.S.C. §1141j. For more information and renewal forms for the international registration, see <http://www.wipo.int/madrid/en/>.

**NOTE: Fees and requirements for maintaining registrations are subject to change. Please check the USPTO website for further information. With the exception of renewal applications for registered extensions of protection, you can file the registration maintenance documents referenced above online at <http://www.uspto.gov>.**

**NOTE: A courtesy e-mail reminder of USPTO maintenance filing deadlines will be sent to trademark owners/holders who authorize e-mail communication and maintain a current e-mail address with the USPTO. To ensure that e-mail is authorized and your address is current, please use the Trademark Electronic Application System (TEAS) Correspondence Address and Change of Owner Address Forms available at <http://www.uspto.gov>.**